An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression.

ABSTRACT:

Objectives

To determine whether molecular remission defined by a multi-biomarker disease activity (MBDA) score predicts a reduced risk of joint damage progression, and whether the MBDA score can augment existing classifications of remission.

Methods

The study examined 271 visits for 163 RA patients in the Leiden Early Arthritis Cohort. The MBDA score and other variables from each visit were evaluated for prediction of progression [change in Sharp-van der Heijde Score (ΔSHS) >3] over the ensuing 12 months. Positive likelihood ratios (PLRs) for non-progression were calculated for remission based upon DAS based on 28-joint counts and CRP (DAS28-CRP <2.32), EULAR/ACR Boolean criteria and MBDA score (≤25).

Results

Ninety-three per cent of patients in MBDA-defined remission

SUBMITTER: van der Helm-van Mil AH 

PROVIDER: S-EPMC3630394 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature